Trial reportNature biotechnology2024
Encapsulated stem cell-derived β cells exert glucose control in patients with type 1 diabetes.
Trial report in Nature biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03163511 (An Open-Label, First-In-Human Study Evaluating the Safety, Tolerability, and Efficacy of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness), which is not on this map. Cited by 78 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-Label, First-In-Human Study Evaluating the Safety, Tolerability, and Efficacy of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness
Who cites it
78 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.
- Efficacy of mesenchymal stromal cells in the treatment of type 1 diabetes: a systematic review.Cell and tissue banking · 2024Pooled it
- Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies.Science advances · 2026Article
- Sodium tungstate promotes vascularization to support beta cell replacement in diabetes.EMBO molecular medicine · 2026Article
- The comparative cell physiology of stem cell-derived and primary human β cells.Nature reviews. Endocrinology · 2026Review
- Localized immunomodulation with cytokine-producing cells to mitigate foreign body responses in rodents and a nonhuman primate.Science advances · 2026Article
- Markers of beta cell and alpha cell mass in human stem cell-generated implants with glycemic control at human setpoint.Stem cells translational medicine · 2026Article
- Stem cell-based therapies for type 1 diabetes: Progress in differentiation, clinical translation, and immune protection.Animal models and experimental medicine · 2026Review
- Modeling immune responses to autologous and allogeneic human stem cell-derived islet grafts in vivo.JCI insight · 2026Article
- Engineering the oxygen microenvironment for pancreatic islet transplants.NPJ Regenerative medicine · 2026Review
- Review
- Clinical translational research on stem cell products: prospects and challenges.Signal transduction and targeted therapy · 2026Review
- Label-Free Optical Sensor for Real-Time Monitoring of Insulin Secretion from Single Human Pancreatic Islets.Sensors (Basel, Switzerland) · 2026Article
- Diurnal Variation of Islet Autoantibody Titers in Established Type 1 Diabetes Suggests Restricted-Time Sampling Improves Aab Measurement and Detection.Research square · 2026Article
- Quantitative β-Cell Mass Imaging Redefines Disease Staging and Glycemic Control in Type 1 Diabetes.Diabetes · 2026Article
- Antigen-specific immunotherapy with a CD4Nature communications · 2026Article
- Deep learning for predicting stem cell efficiency for use in beta cell differentiation.Scientific reports · 2026Article
- Pathogenesis and advances in immunotherapy for type 1 diabetes treatment.Biotechnology reports (Amsterdam, Netherlands) · 2026Review
- Organoid Technology as a Promising Frontier in Organ Transplantation and Regenerative Medicine.International journal of stem cells · 2026Review
- Cell therapy strategies for organ regeneration.BMC medicine · 2026Review
- Human donor islets coated with functionalized chitosan and alginate nanoscale layers can restore normoglycemia in diabetic mice.Materials today. Bio · 2026Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 4 countries.
Funding
Abstract
Clinical studies on the treatment of type 1 diabetes with device-encapsulated pancreatic precursor cells derived from human embryonic stem cells found that insulin output was insufficient for clinical benefit. We are conducting a phase 1/2, open-label, multicenter trial aimed at optimizing cell engraftment (ClinicalTrials.gov identifier: NCT03163511 ). Here we report interim, 1-year outcomes in one study group that received 2-3-fold higher cell doses in devices with an optimized membrane perforation pattern. β cell function was measured by meal-stimulated plasma C-peptide levels at 3-month intervals, and the effect on glucose control was assessed by continuous glucose monitoring (CGM) and insulin dosing. Of 10 patients with undetectable baseline C-peptide, three achieved levels ≥0.1 nmol l
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.